According to the Zhitong Finance App, Gacos-B (01167.HK) announced that the pan-KRAS inhibitor Jab-23E73, developed independently by the company, completed the administration of the first phase I/Ia clinical trial to patients in the US. Currently, dose-escalation studies of this drug in China are also progressing smoothly according to the plan.

Zhitongcaijing · 07/02/2025 00:09
According to the Zhitong Finance App, Gacos-B (01167.HK) announced that the pan-KRAS inhibitor Jab-23E73, developed independently by the company, completed the administration of the first phase I/Ia clinical trial to patients in the US. Currently, dose-escalation studies of this drug in China are also progressing smoothly according to the plan.